Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
|Articles|September 27, 1995
MBI to begin phase-III trials for FS069
Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left
Advertisement
Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left ventricularopacification and to enhance endocardial border delineation. MBIdeveloped Albunex, which is marketed in the U.S. by MallinckrodtMedical. Mallinckrodt also has marketing rights to FS069 (SCAN9/13/95).
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
Catch up on the latest imaging research presented at the recent American Society for Radiation Oncology (ASTRO) Annual Meeting.
Tightness of the high-convexity sulci (THC) on brain MRI was associated with nearly threefold higher odds of cognitive decline over five to seven years of follow-up, according to a new prospective study involving over 2,100 community-dwelling senior citizens.
An AI model for prostate MRI offered an 89 percent AUC for prostate cancer detection in external validation testing, according to a newly published international multicenter study.
In the latest episode of her Breast Imaging in Focus series, Manisha Bahl, MD, MPH, FSBI, discusses new research comparing mammography-based AI models for breast cancer detection and short-term risk prediction.
In a recent episode of our Molecular Imaging in Focus series, Jack Andrews, MD, discussed pertinent findings from a recent intra-patient comparative study of PSMA PET agents in men with recurrent prostate cancer presented at the recent ASTRO conference.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What a Large Prostate MRI Study Reveals About AI and Unassisted Radiologist Assessment
2
FDA Clears First MRI-Derived AI Software for Assessing Breast Cancer Recurrence Risk
3
How Photon-Counting CT Helps Us Recognize that Coronary Stenosis is Just One Piece of the Puzzle
4
Breast Imaging in Focus: Can AI Models for Breast Cancer Detection and Risk Prediction Be Used Interchangeably?
5